JNY Stock Overview
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
JW (Cayman) Therapeutics Co. Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.20 |
| 52 Week High | HK$0.33 |
| 52 Week Low | HK$0.18 |
| Beta | 2.08 |
| 1 Month Change | -11.50% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -10.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| JNY | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.5% | 1.8% | 1.1% |
| 1Y | n/a | -23.5% | 1.9% |
Return vs Industry: Insufficient data to determine how JNY performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how JNY performed against the German Market.
Price Volatility
| JNY volatility | |
|---|---|
| JNY Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: JNY has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine JNY's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 398 | James Li | www.jwtherapeutics.com |
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People’s Republic of China. It offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers.
JW (Cayman) Therapeutics Co. Ltd Fundamentals Summary
| JNY fundamental statistics | |
|---|---|
| Market cap | €86.09m |
| Earnings (TTM) | -€98.91m |
| Revenue (TTM) | €22.39m |
3.8x
P/S Ratio-0.9x
P/E RatioIs JNY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JNY income statement (TTM) | |
|---|---|
| Revenue | CN¥173.86m |
| Cost of Revenue | CN¥85.64m |
| Gross Profit | CN¥88.22m |
| Other Expenses | CN¥856.22m |
| Earnings | -CN¥768.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.90 |
| Gross Margin | 50.74% |
| Net Profit Margin | -441.74% |
| Debt/Equity Ratio | 15.6% |
How did JNY perform over the long term?
See historical performance and comparison